Nerolidol Attenuates Diabetic Embryopathy in Streptozotocin-induced Diabetic Pregnant Rats by Reducing Embryonic and Maternal Oxidative Stress

ABSTRACT

Background: Pregnancy complicated by diabetes leads to congenital disorders, spontaneous abortion, and neonatal morbidity and mortality, which are termed diabetic embryopathy or fetopathy. Objectives: In this work, we planned to investigate the therapeutic potentials of nerolidol against streptozotocin (STZ)- induced diabetic embryopathy in rats through attenuating maternal and fetal oxidative stress. Materials and Methods: The male and female Wistar rats were allowed to mate for a night at a 1:1 ratio. After the confirmation of pregnancy, the rats were administered 40 mg/kg of STZ (i.p.) to initiate diabetes and treated with 20 and 40 mg/kg of nerolidol. The changes in food intake, body weight, blood glucose, and urine output were regularly monitored. The levels of lipid profiles were estimated using assay kits. The oxidative stress and antioxidant biomarkers in the liver tissues and embryonic fractions were measured using assay kits. Results: The nerolidol treatment considerably depleted the blood glucose and urine output and augmented the body weight and diet intake in diabetic rats. The nerolidol suppressed the cholesterol (Ch), triglycerides (TG), and very low density lipoprotein (VLDL) and elevated the high density lipoprotein (HDL) level in diabetic pregnant rats. The maternal and embryonic oxidative stress levels are effectively reduced by the nerolidol treatment by decreasing the malondialdehyde (MDA) and reactive oxygen species (ROS) levels. The levels of antioxidants were also increased by the nerolidol on both liver and embryonic fractions of diabetic pregnant rats. Conclusion: Our results exhibited that the nerolidol treatment considerably reduced embryonic and maternal oxidative stress and embryonic deaths. Hence, it can be a hopeful therapeutic candidate to treat diabetic embryopathy.

KEYWORDS

• Dyslipidemia
• Embryonic death
• Streptozotocin
• Congenital disorder
• Nerolidol

Showing references and in-text citations exactly as published.

Cite this article

• DOI10.1177/09731296231158479Copy

RELATED ARTICLES

Matched on section and article type within this issue of Pharmacogn. Mag..

• Article · VOLUME 19, ISSUE 2In vitro Antioxidant and Anti-inflammatory Effects of Erythroxylum cuneatum Leaf Extract on Oxidized Low-density Lipoprotein-stimulated Human Aortic Endothelial CellsSiti Khadijah Adam, Nitya Shanmugam, Sharlina Mohamad, Shamima Abd Rahman, Mohamad Aris Mohd Moklas · pp. 203–213Original ArticleSame type: Article
• Article · VOLUME 19, ISSUE 2Ethacridine Regulation of JAK/STAT/ERK Signaling Pathway in Colon Cancer Cells SW620: In vitro ApproachHui Zhang, Hui Yang, Wei Wei, Jing Zhao, Annamalai Vijayalakshmi, Minhong Wang · pp. 214–221Original ArticleSame type: Article
• Article · VOLUME 19, ISSUE 2LC-MS/MS-based Targeted Metabolomic Profiling of Aqueous and Hydro-alcoholic Extracts of Pistacia integerrima Linn., Quercus infectoria Olivier and Terminalia chebula RetzAnil Kumar Saini, Laxman Sawant, Sultan Zahiruddin, Dhiraj Shrivastva, Ranjan Mitra, Rajiva Kumar Rai, Sayeed Ahmad · pp. 222–230Original ArticleSame type: Article
• Article · VOLUME 19, ISSUE 2Amelioration of AlCl3-induced Memory Loss in the Rats by an Aqueous Extract of Guduchi, a Medhya RasayanaShrirang B. Jamadagni, Pooja M. Ghadge, Mukul S. Tambe, Marimuthu Srinivasan, Goli Penchala Prasad, Pallavi S. Jamadagni, Shyam Baboo Prasad, Sharad D. Pawar, Arun M. Gurav, Sudesh N. Gaidhani, Y. R. Sanjay Kumar, Narayanam Srikanth · pp. 231–243Original ArticleSame type: Article